BeOne Medicines Ltd. (SHA:688235)
224.63
-11.03 (-4.68%)
Aug 8, 2025, 3:00 PM CST
BeOne Medicines Employees
BeOne Medicines had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees
11,000
Change (1Y)
400
Growth (1Y)
3.77%
Revenue / Employee
2.97M CNY
Profits / Employee
-115.69K CNY
Market Cap
227.78B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11,000 | 400 | 3.77% |
Dec 31, 2023 | 10,600 | 1,600 | 17.78% |
Dec 31, 2022 | 9,000 | 1,000 | 12.50% |
Dec 31, 2021 | 8,000 | 2,700 | 50.94% |
Dec 31, 2020 | 5,300 | 1,800 | 51.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Jiangsu Hengrui Medicine | 20,238 |
Shenzhen Mindray Bio-Medical Electronics | 21,667 |
WuXi AppTec | 39,414 |
Sichuan Biokin Pharmaceutical | 2,521 |
Zhangzhou Pientzehuang Pharmaceutical., | 2,839 |
Aier Eye Hospital Group | 42,693 |
Shanghai United Imaging Healthcare | 8,173 |
Yunnan Baiyao Group Co.,Ltd | 9,277 |
BeOne Medicines News
- 2 days ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 4 days ago - BeiGene's Earnings: A Preview - Benzinga
- 4 days ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 6 weeks ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 2 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn
- 2 months ago - Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
- 2 months ago - BeiGene gets EU backing for neck and head cancer treatment - Seeking Alpha
- 3 months ago - Market Shrugs Off This Drugmaker's Turnaround - Benzinga